Inclusion Criteria:

          -  Patient must pathologically documented stage IV breast cancer.

          -  Tumor must be HER-2 negative, and estrogen and progesterone receptors negative.
             Patients with BRCA 1 or 2 mutations will not be included.

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension.

          -  Biopsy of a metastatic lesion is not required for protocol entry but all patients with
             reasonably accessible lesions must agree to biopsy. (Lung and brain metastasis will
             not be biopsied.) Patients with no reasonably accessible lesions can be enrolled in
             the trial.

          -  Prior Therapy:

               -  No more than two regimens in the metastatic setting as long as patients have
                  adequate performance status. Patients with no prior chemotherapy for metastatic
                  disease may be included in the trial if they received anthracyclines and taxanes
                  in the adjuvant or neoadjuvant settings. Chemotherapy naïve patients with
                  metastatic disease must have failed anthracyclines and taxanes.

               -  Chemotherapy treatment prior to enrollment must be discontinued for at least 3
                  weeks prior to study entry.

               -  Patients must have completed radiation therapy at least 21 days prior to
                  beginning protocol treatment.

          -  Patients must have recovered from all reversible toxicities related to prior therapy
             before beginning protocol treatment and may not have an pre- existing
             treatment-related toxicities higher than Grade 2. Patients must have less than Grade 2
             pre-existing peripheral neuropathy.

          -  Patients may receive bisphosphonates. However, if used, bone lesions may not be used
             for progression or response.

          -  At least 19 years of age.

          -  Life expectancy of >12 weeks.

          -  Performance status according to Eastern Cooperative Oncology Group (ECOG) is less than
             or equal to 2.

          -  Patients must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count: greater than or equal to 1,000/uL

               -  Hemoglobin: greater than or equal to 9 mg/dL

               -  Platelets: greater than or equal to 100,000/uL

               -  Total bilirubin: less than or equal to 1.5 times the institutional upper limit of
                  normal

               -  AST (SGOT)/ALT (SGPT): less than or equal to 2.5 times the institutional upper
                  limit of normal without liver metastases OR less than or equal to 5 times the
                  institutional upper limit of normal if documented liver metastases

               -  Creatinine: less than or equal to 1.5 mg/dL OR calculated creatinine clearance
                  greater than or equal to 40 mL/min (calculated using the modified Cockcroft and
                  Gault method).

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Use of an effective means of contraception in subjects of child-bearing potential.

          -  Negative serum or urine beta-HCG (human chorionic gonadotropin) pregnancy test at
             screening for patients with childbearing potential.

          -  Ejection fraction must be 50%.

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents.

          -  No prior use of anthracyclines and taxanes for metastatic disease or in the adjuvant
             or neoadjuvant setting.

          -  Metastatic lesions identifiable only by PET.

          -  QTc (corrected QT) >470 msec. Excluded are patients who may develop prolongation of
             QTc. These conditions include patients with hypokalemia or hypomagnesemia, congenital
             long QT syndrome, patients taking anti- arrhythmic medicines or other medicinal
             products that lead to QT prolongation, and cumulative high-dose anthracycline therapy.

          -  Patients may not be receiving concurrent chemotherapy for treatment of metastatic
             disease.

          -  Active brain metastases: evidence of progression less than or equal to 3 months after
             local therapy. (Patients should be asymptomatic and off corticosteroids and
             anticonvulsants for at least 3 months prior to study entry).

          -  Patients with brain metastases must have at least one site of measurable disease
             outside of the central nervous system.

          -  Uncontrolled concurrent illness including, but not limited to, ongoing or active
             infection, history of recent myocardial infarction, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          -  Uncontrolled seizure disorder.

          -  Pregnant or lactating women are excluded. Because there is an unknown but potential
             risk for adverse events in nursing infants secondary to treatment of the mother,
             breastfeeding should be discontinued if the mother is treated. These potential risks
             may also apply to other agents used in this study.

          -  A prior invasive malignant disease within five years except for skin cancer (squamous
             cell or basal cell carcinoma).

          -  Patients with known history of HIV or Hepatitis B because of potential for added
             toxicity from treatment regimen.

          -  Dementia or altered mental status that would prohibit the understanding of informed
             consent.